{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:08:30Z","timestamp":1788858510825,"version":"build-2803163510"},"reference-count":62,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: HER2-directed antibody\u2013drug conjugates have expanded the clinical relevance of low-level HER2 expression. However, the prevalence and clinical significance of HER2-ultralow expression in gynecologic malignancies remain insufficiently defined. This study characterized the full spectrum of HER2 expression in endometrial carcinoma (EC) and high-grade serous ovarian carcinoma (HGSOC), including matched metastatic lesions. Methods: HER2 expression was assessed by immunohistochemistry in tissue microarrays from 117 EC and 52 HGSOC patients. Available matched metastatic lesions were analyzed in 23 EC and 18 HGSOC cases. HER2 expression was categorized as zero, ultralow, 1+, 2+, or 3+. Associations with clinicopathological parameters and progression-free survival were evaluated. Results: HER2-ultralow expression was common in primary tumors, occurring in 49\/117 EC cases (41.9%) and 11\/52 HGSOC cases (21.2%), whereas HER2 3+ expression was rare (EC: 2\/117, 1.7%; HGSOC: 1\/52, 1.9%). HER2 expression in primary tumors was associated with progression-free survival in both entities, with HER2-zero tumors showing the longest estimated progression-free survival. HER2 score discordance between matched primary tumors and metastases occurred in 16\/23 EC cases (69.6%) and 8\/18 HGSOC cases (44.4%). Conclusions: HER2-ultralow expression represents a frequent and previously underrecognized category in EC and HGSOC. While its prognostic impact remains limited, the high prevalence of HER2-ultralow tumors suggests potential relevance for future HER2-targeted therapeutic strategies. Prospective studies are needed to determine whether this subgroup may benefit from a HER2-targeted therapy.<\/jats:p>","DOI":"10.3390\/cancers18172843","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:39:47Z","timestamp":1788363587000},"page":"2843","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expression of HER2 Ultralow in Endometrial Carcinoma, High-Grade Serous Ovarian Cancer and Their Metastases"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2140-5547","authenticated-orcid":false,"given":"C.","family":"Backhaus","sequence":"first","affiliation":[{"name":"Clinic for Gynecology and Obstetrics, University Medical Center of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"A.","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Clinic for Gynecology and Obstetrics, University Medical Center of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"V.","family":"Guyon","sequence":"additional","affiliation":[{"name":"Clinic for Gynecology and Obstetrics, University Medical Center of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"D.","family":"Wei\u00df","sequence":"additional","affiliation":[{"name":"Clinic for Gynecology and Obstetrics, University Medical Center of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"software","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"M.","family":"Werner","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center of Freiburg, 79106 Freiburg, Germany"},{"name":"Core Facility for Histopathology and Digital Pathology, University Medical Center of Freiburg, 79106 Freiburg, Germany"},{"name":"Comprehensive Cancer Center, University Medical Center of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8558-0347","authenticated-orcid":false,"given":"P.","family":"Bronsert","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center of Freiburg, 79106 Freiburg, Germany"},{"name":"Core Facility for Histopathology and Digital Pathology, University Medical Center of Freiburg, 79106 Freiburg, Germany"},{"name":"Comprehensive Cancer Center, University Medical Center of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"given":"P.","family":"Gro\u00df","sequence":"additional","affiliation":[{"name":"Clinic for Gynecology and Obstetrics, University Medical Center of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"software","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2178-6490","authenticated-orcid":false,"given":"I.","family":"Juhasz-B\u00f6ss","sequence":"additional","affiliation":[{"name":"Clinic for Gynecology and Obstetrics, University Medical Center of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0448-7999","authenticated-orcid":false,"given":"K.","family":"Kurowski","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center of Freiburg, 79106 Freiburg, Germany"},{"name":"Core Facility for Histopathology and Digital Pathology, University Medical Center of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ref_1","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2024). Global Cancer Observatory: Cancer Today (Version 1.1), International Agency for Research on Cancer."},{"key":"ref_2","unstructured":"American Cancer Society (2025). Cancer Facts & Figures 2025, American Cancer Society."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2021.01.036","article-title":"Variations in Incidence and Mortality Rates of Endometrial Cancer at the Global, Regional, and National Levels, 1990\u20132019","volume":"161","author":"Gu","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial Cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ygyno.2018.05.015","article-title":"Endometrial Cancer: Molecular Markers and Management of Advanced Stage Disease","volume":"150","author":"Arend","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP Guidelines for the Management of Patients with Endometrial Carcinoma: Update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results from the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e390772","DOI":"10.1200\/EDBK_390772","article-title":"Antibody-Drug Conjugates in Gynecologic Cancer","volume":"43","author":"Karpel","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_10","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Papageorgiou, D., Liouta, G., Pliakou, E., Zachariou, E., Sapantzoglou, I., Prokopakis, I., and Kontomanolis, E.N. (2025). Management of Advanced Ovarian Cancer: Current Clinical Practice and Future Perspectives. Biomedicines, 13.","DOI":"10.3390\/biomedicines13071525"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Punz\u00f3n-Jim\u00e9nez, P., Lago, V., Domingo, S., Sim\u00f3n, C., and Mas, A. (2022). Molecular Management of High-Grade Serous Ovarian Carcinoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213777"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour Les Etudes Des Cancers de l\u2019Ovaire (GINECO)","volume":"115","author":"Reuss","year":"2009","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.2999974","article-title":"Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with Neu Oncogene","volume":"230","author":"Coussens","year":"1985","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The Oncogene HER2: Its Signaling and Transforming Functions and Its Role in Human Cancer Pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41698-025-01209-9","article-title":"HER2 Expression in Breast Cancer: Evidence Gaps and Challenges","volume":"10","author":"Atallah","year":"2026","journal-title":"npj Precis. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/OP.21.00172","article-title":"Current and Future Management of HER2-Positive Metastatic Breast Cancer","volume":"17","author":"Prat","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S1213","DOI":"10.1016\/j.annonc.2024.08.2259","article-title":"LBA21 Human Epidermal Growth Factor Receptor 2 (HER2)-Low and HER2-Ultralow Status Determination in Tumors of Patients (Pts) with Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (mBC) in DESTINY-Breast06 (DB-06)","volume":"35","author":"Salgado","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_22","first-page":"e2025-0593-C","article-title":"Navigating Human Epidermal Growth Factor Receptor 2 (HER2) Assessment by Organ Systems: A Guidebook to HER2 Testing in Solid Tumors","volume":"1","author":"Turashvili","year":"2026","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_23","unstructured":"Allison, K.H., and Krishnamurti, U. (2026, August 25). Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. Available online: https:\/\/www.cap.org\/wp-content\/uploads\/2026\/07\/Breast.Bmk_1.6.1.0.-REL_CAPCP-1.pdf?download=true."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","article-title":"Gynecologic Oncology Group An Exploratory Analysis of HER-2 Amplification and Overexpression in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study","volume":"108","author":"Grushko","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0002-9378(91)90615-X","article-title":"Overexpression of HER-2\/Neu in Endometrial Cancer Is Associated with Advanced Stage Disease","volume":"164","author":"Berchuck","year":"1991","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF01606911","article-title":"Immunohistochemical Localization of C-erbB-2 Protein and Epidermal Growth Factor Receptor in Normal Surface Epithelium, Surface Inclusion Cysts, and Common Epithelial Tumours of the Ovary","volume":"421","author":"Wang","year":"1992","journal-title":"Virchows Arch. A Pathol. Anat. Histopathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tuefferd, M., Couturier, J., Penault-Llorca, F., Vincent-Salomon, A., Bro\u00ebt, P., Guastalla, J.-P., Allouache, D., Combe, M., Weber, B., and Pujade-Lauraine, E. (2007). HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0001138"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1055\/s-2002-32269","article-title":"Expression of c-erbB-2 and Topoisomerase II Alpha in Relation to Chemoresistance in Ovarian Cancer","volume":"124","author":"Tanner","year":"2002","journal-title":"Zentralbl. Gynakol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Liu, L., Cheng, N., Kong, F., and Shen, D. (2025). Human Epidermal Growth Factor Receptor 2 Expression in Gynecologic Serous Carcinomas and Preliminary Analysis of Its Characteristics in Patients Post-Neoadjuvant Chemotherapy. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1618237"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results from the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.3802\/jgo.2023.34.e85","article-title":"FIGO Staging of Endometrial Cancer: 2023","volume":"34","author":"Berek","year":"2023","journal-title":"J. Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the Ovary, Fallopian Tube, and Peritoneum: 2021 Update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_34","unstructured":"WHO Classification of Tumours Editorial Board (2020). Female Genital Tumours. WHO Classification of Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kurowski, K., Timme, S., F\u00f6ll, M.C., Backhaus, C., Holzner, P.A., Bengsch, B., Schilling, O., Werner, M., and Bronsert, P. (2024). AI-Assisted High-Throughput Tissue Microarray Workflow. Methods Protoc., 7.","DOI":"10.3390\/mps7060096"},{"key":"ref_36","unstructured":"Roche Diagnostics (2022). PATHWAY Anti-HER-2\/Neu (4B5) Rabbit Monoclonal Primary Antibody: Package Insert 14427EN Rev H, Ventana Medical Systems, Inc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00428-009-0728-8","article-title":"Comprehensive Immunohistochemical Analysis of Her-2\/Neu Oncoprotein Overexpression in Breast Cancer: HercepTest (Dako) for Manual Testing and Her-2\/neuTest 4B5 (Ventana) for Ventana BenchMark Automatic Staining System with Correlation to Results of Fluorescence in Situ Hybridization (FISH)","volume":"454","author":"Mayr","year":"2009","journal-title":"Virchows Arch."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PAI.0b013e3181f7118e","article-title":"Testing HER2 in Breast Cancer: A Comparative Study on BRISH, FISH, and IHC","volume":"19","author":"Lelkaitis","year":"2011","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open Source Software for Digital Pathology Image Analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.0006-341X.2001.00114.x","article-title":"A Solution to the Problem of Monotone Likelihood in Cox Regression","volume":"57","author":"Heinze","year":"2001","journal-title":"Biometrics"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/13543784.2024.2376573","article-title":"Trastuzumab-Deruxtecan in Solid Tumors with HER2 Alterations: From Early Phase Development to the First Agnostic Approval of an Antibody-Drug Conjugate","volume":"33","author":"Edoardo","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00428-010-0952-2","article-title":"HER2 Diagnostics in Gastric Cancer-Guideline Validation and Development of Standardized Immunohistochemical Testing","volume":"457","author":"Dietel","year":"2010","journal-title":"Virchows Arch."},{"key":"ref_45","unstructured":"Crothers, B.A., Harik, L.R., Bartley, A.N., Broaddus, R.R., Chuang, L.T., Cohen, M.B., Jamieson, P.S., Jarboe, E.A., Longacre, T.A., and Mutter, G.L. (2026, August 24). Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of Gynecologic Origin. Available online: https:\/\/www.cap.org\/download.php?file=wp-content\/uploads\/protocols\/Gynecologic.Bmk_1.0.0.0.REL_CAPCP.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2\/Neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.3802\/jgo.2026.37.e65","article-title":"Trastuzumab Deruxtecan in HER2-Expressing Gynecologic Cancers from DESTINY-PanTumor02: Antitumor Activity, Safety, and Exploratory Biomarker Analyses","volume":"37","author":"Lee","year":"2026","journal-title":"J. Gynecol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2025.10.034","article-title":"Comparison of Breast and Gastric HER2 Immunohistochemistry (IHC) Scoring Criteria in the Assessment of Endometrial Carcinoma","volume":"204","author":"Furuya","year":"2026","journal-title":"Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2025.05.017","article-title":"The Evolving Role of HER2 in Gynecologic Oncology and Clinical Trial Design: A Gynecologic Pathologist\u2019s Perspective","volume":"198","author":"Ehimiaghe","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s44276-025-00125-6","article-title":"HER2 Amplification and HER2 Low Expression in Endometrial Carcinoma: Prevalence across Molecular, Histological and Clinicopathological Risk Groups","volume":"3","author":"Aro","year":"2025","journal-title":"BJC Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ygyno.2025.10.029","article-title":"Prognostic Implications of HER2 in Ovarian Cancer: Associations with Homologous Recombination Deficiency and Folate Receptor Alpha Expression","volume":"203","author":"Park","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Long-Term Survival Analysis of the Randomized, Phase 3 DESTINY-Breast04 Trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"101592","DOI":"10.1016\/j.esmoop.2023.101592","article-title":"Prognostic Value of HER2-Low Status in Breast Cancer: A Systematic Review and Meta-Analysis","volume":"8","author":"Molinelli","year":"2023","journal-title":"ESMO Open"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2025.07.024","article-title":"HER2 Expression in an Endometrial Cancer Cohort","volume":"201","author":"Hacker","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10555-016-9631-3","article-title":"Estrogen, Progesterone, and HER2\/Neu Receptor Discordance between Primary and Metastatic Breast Tumours\u2014A Review","volume":"35","author":"Yeung","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/IGC.0000000000000015","article-title":"Bone Metastasis in Primary Endometrial Carcinoma: Features, Outcomes, and Predictors","volume":"24","author":"Yoon","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Thomakos, N., Diakosavvas, M., Machairiotis, N., Fasoulakis, Z., Zarogoulidis, P., and Rodolakis, A. (2019). Rare Distant Metastatic Disease of Ovarian and Peritoneal Carcinomatosis: A Review of the Literature. Cancers, 11.","DOI":"10.3390\/cancers11081044"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/jnci\/djx273","article-title":"Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-Analysis","volume":"110","author":"Schrijver","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/bjc.2017.422","article-title":"HER2 Expression Patterns in Paired Primary and Metastatic Endometrial Cancer Lesions","volume":"118","author":"Halle","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/cam4.4600","article-title":"Biomarkers Expression among Paired Serous Ovarian Cancer Primary Lesions and Their Peritoneal Cavity Metastases in Treatment-Na\u00efve Patients: A Single-Center Study","volume":"11","author":"Nikas","year":"2022","journal-title":"Cancer Med."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Yeo, M.-K., Kim, S., Yoo, H.J., Suh, K.-S., and Kim, K.-H. (2022). HER2 Expression in Peritoneal Dissemination of High-Grade Serous Ovarian Carcinoma: A Comparative Study of Immunohistochemical Reactivity Using Four HER2 Antibodies. J. Clin. Med., 11.","DOI":"10.21203\/rs.3.rs-1690181\/v2"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2843\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:21:05Z","timestamp":1788855665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":62,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18172843"],"URL":"https:\/\/doi.org\/10.3390\/cancers18172843","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}